Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment
Bone metastases are devastating complications of cancer. They are particularly common in
prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy …
prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy …
Treatment of advanced prostate cancer
MY Teo, DE Rathkopf, P Kantoff - Annual review of medicine, 2019 - annualreviews.org
The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …
risk stratification and workup, treatment options for localized disease, and management of …
[HTML][HTML] Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …
Genetics and biology of prostate cancer
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears… - … England Journal of …, 2017 - Mass Medical Soc
Background Abiraterone acetate plus prednisolone improves survival in men with relapsed
prostate cancer. We assessed the effect of this combination in men starting long-term …
prostate cancer. We assessed the effect of this combination in men starting long-term …
[HTML][HTML] Plant-derived anticancer agents: A green anticancer approach
Cancer is a frightful disease and represents one of the biggest health-care issues for the
human race and demands a proactive strategy for cure. Plants are reservoirs for novel …
human race and demands a proactive strategy for cure. Plants are reservoirs for novel …